Oral drug test for relapsed or refractory B-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a B-cell cancer such as Waldenström’s macroglobulinemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, DLBCL, hairy cell leukemia, chronic lymphocytic leukemia, or small lymphocytic lymphoma (based on 2016 WHO type).
- If your diagnosis is Waldenström’s, follicular (FL), mantle cell (MCL), DLBCL, or hairy cell leukemia (HCL), you must have already had at least 2 prior cancer treatments.
- Your blood tests and organ function must be adequate: kidney function (creatinine clearance ≥ 60 mL/min), liver enzymes (AST/ALT) and bilirubin (mostly ≤ 1.5× normal), and clotting tests (PT and APTT ≤ 1.5× normal).
- Your bone marrow must make enough cells: neutrophils (ANC) at least 1000 (sometimes growth factor can help), platelets at least 50,000 (or 20,000 in certain CLL cases), and hemoglobin at least 8.0 (blood transfusion is allowed to reach this).
- You must not have had anti-cancer treatment, radiation, or other investigational drugs within 14 days (or 5 half-lives, whichever is shorter) before starting LP-168, and you must be back to low-grade side effects (except hair loss).
- You must be able to avoid certain medicines: strong acid medicines (PPIs must be stopped 7 days before and during the study), and avoid specific liver-enzyme–affecting drugs and Warfarin; also avoid major heart rhythm problems on ECG (QTc ≥ 480ms or certain blocks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial tests a new combination of two drugs, LP-168 and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease has come back or not responded to previous treatments. It may be an option if you have already tried certain therapies, including a BTK inhibitor or a BCL2 inhibitor.
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.